Connect Biopharma Holdings (CNTB) EBT Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported EBT Margin for 3 consecutive years, with 11449.7% the latest figure, recorded in Q1 2026.

• Quarterly EBT Margin changed N/A year-over-year to 11449.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27645.92% (changed N/A YoY) and the FY2025 annual result came in at 86379.69%, down 8632051.0% from the prior year.
• EBT Margin rose to 11449.7% in Q1 2026 per CNTB's latest filing, from 107118.75% in the prior quarter.
• Over the last five years, EBT Margin for CNTB reached as high as 1051.6% in Q3 2024 and fell as low as 107118.75% in Q3 2025.
• A 3-year average of 29527.83% and a median of 11449.7% in 2026 frame the typical range for EBT Margin.
• The largest YoY upside for EBT Margin was 10606715 bps in 2025 against a maximum downside of 10606715 bps in 2025.
• Year by year, EBT Margin stood at 1260.74% in 2024, then sank by 8396 bps to 107118.75% in 2025, then jumped by 89 bps to 11449.7% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 11449.7%, 107118.75%, and 26758.33% for Q1 2026, Q3 2025, and Q2 2025 respectively.